ACADIA PHARMACEUTICALS INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount
ACADIA PHARMACEUTICALS INC. (ACAD) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-02-26
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2024-06-30 was $200.00K, a 77.78% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2024-03-31 was $4.30M, a 1333.33% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2023-12-31 was $3.40M.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $3.60M, a 1100.00% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2022 was $300.00K, a 50.00% decline from fiscal 2021.
- ACADIA PHARMACEUTICALS INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2021 was $600.00K.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | $200.00K derived: sum of 2 quarters · filed 2024-11-07 | $4.50M 10-Q · filed 2024-11-07 | $7.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $200.00K 10-Q · filed 2024-08-07 | $4.50M 10-Q · filed 2024-08-07 | $7.90M derived: sum of 3 quarters · filed 2026-02-26 | $8.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.30M 10-Q · filed 2024-05-09 | $7.70M derived: sum of 2 quarters · filed 2026-02-26 | $8.70M derived: sum of 3 quarters · filed 2026-02-26 | $9.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.40M derived: sum of 2 quarters · filed 2026-02-26 | $5.30M derived: sum of 3 quarters · filed 2026-02-26 | $3.60M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-07 | $1.90M derived: sum of 2 quarters · filed 2024-11-07 | $200.00K 10-Q · filed 2024-11-07 | $2.10M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $900.00K 10-Q · filed 2024-08-07 | $1.20M 10-Q · filed 2024-08-07 | $1.10M derived: sum of 3 quarters · filed 2024-08-07 | $1.10M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-09 | $200.00K derived: sum of 2 quarters · filed 2024-05-09 | $200.30K derived: sum of 3 quarters · filed 2024-05-09 | $201.10K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$99.70K derived: sum of 2 quarters · filed 2024-02-28 | -$98.90K derived: sum of 3 quarters · filed 2024-02-28 | $300.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | $300.00 10-Q · filed 2023-11-03 | $1.10K derived: sum of 2 quarters · filed 2023-11-03 | $400.00K 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $800.00 10-Q · filed 2023-08-03 | $100.00K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $900.00K 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $600.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |